Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$72.35 - $88.99 $1,808 - $2,224
-25 Reduced 1.68%
1,461 $109,000
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $6,298 - $8,025
161 Added 12.15%
1,486 $68,000
Q2 2023

Aug 10, 2023

BUY
$23.58 - $44.68 $5,800 - $10,991
246 Added 22.8%
1,325 $55,000
Q1 2023

May 15, 2023

SELL
$25.42 - $33.52 $5,261 - $6,938
-207 Reduced 16.1%
1,079 $28,000
Q4 2022

Jun 14, 2023

BUY
$18.46 - $36.37 $3,821 - $7,528
207 Added 19.18%
1,286 $38.3 Million
Q4 2022

Mar 30, 2023

SELL
$18.46 - $36.37 $4,282 - $8,437
-232 Reduced 15.28%
1,286 $38,000
Q4 2022

Feb 15, 2023

SELL
$18.46 - $36.37 $4,282 - $8,437
-232 Reduced 15.28%
1,286 $38,000
Q3 2022

Jun 14, 2023

BUY
$13.55 - $19.92 $5,948 - $8,744
439 Added 40.69%
1,518 $29.5 Million
Q2 2022

Jun 20, 2023

BUY
$7.4 - $15.07 $3,248 - $6,615
439 Added 40.69%
1,518 $20,000
Q1 2022

Jun 20, 2023

BUY
$11.65 - $19.57 $5,114 - $8,591
439 Added 40.69%
1,518 $21,000
Q1 2022

Mar 30, 2023

SELL
$11.65 - $19.57 $25,012 - $42,016
-2,147 Reduced 58.58%
1,518 $21,000
Q1 2022

May 12, 2022

SELL
$11.65 - $19.57 $25,012 - $42,016
-2,147 Reduced 58.58%
1,518 $21,000
Q4 2021

Jun 21, 2023

BUY
$18.01 - $30.1 $46,573 - $77,838
2,586 Added 239.67%
3,665 $69,000
Q4 2021

Mar 30, 2023

BUY
$18.01 - $30.1 $6,483 - $10,836
360 Added 10.89%
3,665 $69,000
Q4 2021

Feb 15, 2022

BUY
$18.01 - $30.1 $6,483 - $10,836
360 Added 10.89%
3,665 $70,000
Q3 2021

Jun 21, 2023

BUY
$18.25 - $38.35 $40,624 - $85,367
2,226 Added 206.3%
3,305 $74,000
Q3 2021

Mar 30, 2023

BUY
$18.25 - $38.35 $36,846 - $77,428
2,019 Added 157.0%
3,305 $74,000
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $60,316 - $126,746
3,305 New
3,305 $75,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.62B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.